Recently, biosimilars have made a definite appearance on the FDA’s radar, an expected result after the first biosimilar product gained FDA approval in March and the FDA’s release of four final ("Scientific Considerations in Demonstrating Biosimilarity to a Reference Product," "Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product," "Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009," and "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants.") and one draft guidance regarding biosimilars. The most recent guidance, “Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants,” provides the FDA’s perspective on how good meeting management practices (GMMPs) apply to requesting, preparing, scheduling, and conducting biosimilar meetings and gives key differences from drug and biologic product meetings.
Biosimilars will not follow the traditional meeting structure or format. Most sponsors are familiar with Type A, B, and C meetings for drug and biologic products, for biosimilars, this will not be the case. Five types of meetings have been defined as the means to discuss biosimilar product development (BPD):
Biosimilar Initial Advisory meeting:
BPD Type 1 meeting:
BPD Type 2 meeting:
BPD Type 3 meeting:
BPD Type 4 meeting:
FDA has also changed when meeting packages are to be submitted. The content of the meeting package for biosimilar products is very comparable to that of drugs and biologics, however the meeting package for all biosimilar meetings is required to be submitted with the meeting request letter. In contrast, meeting packages for Type B and C meetings for drugs and biologics can be submitted after the meeting request letter, giving the sponsor additional time to create the meeting package. That is not a valid option for sponsors pursuing a biosimilar meeting.
Maximizing the beneficial outcome of an FDA meeting is a critical component of a drug, biologic, or biosimilar product development plan. Providing a meeting request letter and a robust meeting package simultaneously can be a challenge for sponsors with time restrictions or lack of familiarity with the process. ProPharma Group has extensive experience in preparing FDA meeting request letters and meeting packages and can assist with the creation of meeting documents as well as preparing for FDA meetings. For more information about how we can help you with a critical FDA meeting, please contact us.
If you have any questions or thoughts on this blog post or others, please contact us.
April 7, 2016
On Tuesday, April 5th, FDA announced the approval of Inflectra™ (infliximab-dyyb), a biosimilar version of Janssen Biotech's Remicade® (infliximab), for a number of indications. Inflectra is...
April 27, 2017
On Friday, April 21st, Reneflexis® (SB2, infliximab – abda) was approved by the FDA. Reneflexis is manufactured by Samsung Bioeipis, and is a biosimilar product to Janssen’s Remicade® (infliximab)....
September 6, 2016
On Wednesday, August 30th, the FDA announced the approval of Sandoz’s Erelzi™ (etanercept-szzs). Erelzi is biosimilar to Amgen’s Enbrel® (etanercept) and is indicated for the treatment of multiple...